StocksFundsScreenerSectorsWatchlists
VXRT

VXRT - Vaxart Inc Stock Price, Fair Value and News

0.91USD-0.13 (-12.50%)Market Closed

Market Summary

VXRT
USD0.91-0.13
Market Closed
-12.50%

VXRT Stock Price

View Fullscreen

VXRT RSI Chart

VXRT Valuation

Market Cap

158.2M

Price/Earnings (Trailing)

-1.92

Price/Sales (Trailing)

21.44

EV/EBITDA

-1.68

Price/Free Cashflow

-2.19

VXRT Price/Sales (Trailing)

VXRT Profitability

Operating Margin

-497.64%

EBT Margin

-1114.03%

Return on Equity

-142.66%

Return on Assets

-89.8%

Free Cashflow Yield

-45.71%

VXRT Fundamentals

VXRT Revenue

Revenue (TTM)

7.4M

Rev. Growth (Yr)

14.7K%

Rev. Growth (Qtr)

54.45%

VXRT Earnings

Earnings (TTM)

-82.5M

Earnings Growth (Yr)

27.36%

Earnings Growth (Qtr)

0.14%

Breaking Down VXRT Revenue

Last 7 days

-15.7%

Last 30 days

-19.5%

Last 90 days

62.5%

Trailing 12 Months

33.8%

How does VXRT drawdown profile look like?

VXRT Financial Health

Current Ratio

3.32

VXRT Investor Care

Shares Dilution (1Y)

28.25%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023697.0K2.1M4.2M7.4M
2022471.0K359.0K159.0K107.0K
20211.6M1.2M1.2M892.0K
20207.4M7.8M7.6M4.0M
20198.1M7.5M7.7M9.9M
20185.0M3.8M3.2M4.2M
20175.3M3.2M6.6M5.8M
2016011.5M9.4M7.4M
201523.5M8.4M13.6M0
201469.5M68.7M53.6M38.5M
201324.9M33.6M44.4M52.5M
201214.0M10.9M11.2M19.5M
201130.4M29.3M18.1M16.1M
2010018.7M26.8M35.0M
200900010.5M

Tracking the Latest Insider Buys and Sells of Vaxart Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 28, 2024
cummings james f.
sold (taxes)
-4,279
1.3
-3,292
chief medical officer
Mar 28, 2024
tucker sean
sold (taxes)
-5,072
1.3
-3,902
svp, chief scientific officer
Mar 18, 2024
lee phillip e
acquired
-
-
90,000
chief financial officer
Mar 18, 2024
cummings james f.
acquired
-
-
90,000
chief medical officer
Mar 18, 2024
lo steven
acquired
-
-
250,000
president, chief exec officer
Mar 18, 2024
tucker sean
acquired
-
-
90,000
svp, chief scientific officer
Mar 18, 2024
berg edward b
acquired
-
-
90,000
svp, general counsel
Feb 02, 2024
berg edward b
sold (taxes)
-11,064
1.2
-9,220
svp, general counsel
Feb 02, 2024
cummings james f.
sold (taxes)
-9,558
1.2
-7,965
chief medical officer
Feb 02, 2024
tucker sean
sold (taxes)
-11,064
1.2
-9,220
svp, chief scientific officer

1–10 of 50

Which funds bought or sold VXRT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 11, 2024
Birch Capital Management, LLC
new
-
43.00
43.00
-%
Apr 05, 2024
NBC SECURITIES, INC.
new
-
1,000
1,000
-%
Mar 11, 2024
VANGUARD GROUP INC
added
1.27
-1,210,100
4,035,360
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
sold off
-100
-13,876
-
-%
Feb 26, 2024
Virtu Financial LLC
new
-
25,000
25,000
-%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
added
72.65
67,000
280,000
0.02%
Feb 16, 2024
HARBOUR INVESTMENTS, INC.
sold off
-100
-1,138
-
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
unchanged
-
-15,000
45,000
-%
Feb 15, 2024
JANE STREET GROUP, LLC
reduced
-48.65
-19,275
12,328
-%
Feb 14, 2024
BNP PARIBAS FINANCIAL MARKETS
unchanged
-
-601
1,901
-%

1–10 of 44

Are Funds Buying or Selling VXRT?

Are funds buying VXRT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own VXRT
No. of Funds

Unveiling Vaxart Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
4.63%
7,044,971
SC 13G/A
Jan 19, 2024
ra capital management, l.p.
9.1%
15,384,615
SC 13G
Jul 07, 2023
blackrock inc.
1.3%
1,928,709
SC 13G/A
Feb 09, 2023
vanguard group inc
5.35%
7,019,507
SC 13G
Feb 01, 2023
blackrock inc.
6.7%
8,858,225
SC 13G/A
Jan 10, 2023
state street corp
1.83%
2,398,264
SC 13G/A
Mar 10, 2022
state street corp
10.39%
13,072,021
SC 13G/A
Feb 11, 2022
state street corp
8.91%
11,187,642
SC 13G/A
Feb 07, 2022
blackrock inc.
6.7%
8,452,420
SC 13G
Feb 11, 2021
state street corp
8.63%
9,444,967
SC 13G

Recent SEC filings of Vaxart Inc

View All Filings
Date Filed Form Type Document
Apr 01, 2024
4
Insider Trading
Apr 01, 2024
4
Insider Trading
Apr 01, 2024
4/A
Insider Trading
Mar 20, 2024
3
Insider Trading
Mar 20, 2024
4
Insider Trading
Mar 20, 2024
4
Insider Trading
Mar 20, 2024
4
Insider Trading
Mar 20, 2024
4
Insider Trading
Mar 20, 2024
4
Insider Trading
Mar 14, 2024
8-K
Current Report

Peers (Alternatives to Vaxart Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
40.2B
6.8B
-1.24% -34.47%
-8.53
5.87
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
18.7B
1.8B
0.05% -28.38%
-42.48
10.23
76.23% 61.08%
17.4B
2.4B
8.82% -6.19%
103.82
7.19
15.42% 18.43%
12.1B
3.7B
-8.57% -28.49%
20.24
3.27
8.87% 75.42%
MID-CAP
6.2B
396.6M
-9.73% -34.59%
-11.81
15.74
425.83% 18.94%
4.7B
-
-4.69% 71.46%
-7.23
60.35
54.84% -34.79%
3.3B
270.6M
-0.99% 6.40%
-13.71
12.12
440.80% -27.84%
3.1B
240.7M
-13.54% -18.95%
-10.32
12.72
-1.03% -92.09%
2.8B
726.4M
-12.42% -7.51%
-46.06
3.89
40.45% 71.62%
SMALL-CAP
1.8B
398.2M
-8.48% -15.36%
25.1
4.5
85.90% -14.05%
599.0M
983.7M
-18.48% -55.04%
-1.1
0.61
-50.36% 17.16%
428.3M
881.7K
-13.30% 407.71%
-9.6
466.16
-77.61% -5.33%
257.8M
4.9M
-1.96% -2.22%
-1.91
52.97
-54.97% 51.72%
7.2M
2.1M
77.59% 88.99%
-0.26
2.14
-13.45% 66.37%

Vaxart Inc News

Latest updates
MarketBeat22 Mar 202407:00 am
Seeking Alpha14 Mar 202407:00 am
Yahoo Finance26 Feb 202408:00 am
Yahoo Finance20 Feb 202408:00 am
InvestorPlace10 months ago

Vaxart Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue54.5%3,245,0002,101,0001,358,000675,00022,000--85,00074,000200,000112,000506,000356,000265,000523,0002,902,0003,916,000454,00085,0005,407,0001,767,000
Operating Expenses1.1%20,145,00019,923,00024,411,00026,247,00031,160,00029,426,00029,247,00024,861,00024,289,00017,451,00015,887,00016,017,00013,717,0007,854,0009,049,0003,596,0009,542,0005,168,0005,082,0005,855,0005,953,000
  S&GA Expenses10.5%5,440,0004,921,0005,598,0006,625,0006,447,0006,960,0009,321,0006,658,0005,754,0005,042,0005,150,0005,944,0005,126,0004,190,0003,896,0001,990,0001,331,0001,455,0001,375,0002,026,0001,226,000
  R&D Expenses-2.0%14,705,00015,002,00018,813,00019,622,00020,459,00022,466,00019,926,00018,203,00015,530,00012,409,00010,737,00010,073,0008,591,0004,616,0005,114,0001,542,0003,291,0003,713,0003,707,0003,829,0004,474,000
EBITDA Margin48.7%-9.97-19.42-45.33-144-952-625-245-159-74.16-50.74-40.71-26.47---------
Interest Expenses-----------------27,00084,00097,000107,000119,000
Income Taxes346.2%174,00039,00019,00029,00016,00016,00015,00020,00018,00021,00030,00038,00033,00026,00026,000153,000196,00031,00013,000250,00080,000
Earnings Before Taxes0.9%-17,201,000-17,361,000-22,531,000-25,111,000-23,902,000-29,293,000-29,415,000-25,081,000-20,746,000-17,562,000-16,086,000-15,969,000-13,828,000-8,059,000-8,951,000-1,144,000-6,213,000-5,229,000-5,624,000-1,089,000-4,822,000
EBT Margin47.9%-11.14-21.39-49.07-154-1,006-657-258-168-78.88-54.04-43.54-28.37---------
Net Income0.1%-17,375,000-17,400,000-22,550,000-25,140,000-23,918,000-29,309,000-29,430,000-25,101,000-20,764,000-17,583,000-16,116,000-16,007,000-13,861,000-8,085,000-8,977,000-1,297,000-6,409,000-5,260,000-5,637,000-1,339,000-4,902,000
Net Income Margin47.8%-11.18-21.42-49.11-154-1,007-657-258-168-79.00-54.15-43.64-28.44---------
Free Cashflow12.2%-13,417,000-15,283,000-17,925,000-25,699,000-33,053,000-16,643,000-28,225,000-26,459,000-16,829,000-15,591,000-15,362,000-17,207,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-13.1%92.0010612313015417518120022124122920615315564.0053.0037.0043.0037.0036.0035.00
  Current Assets-20.3%46.0057.0071.0076.0099.0012013815416919218917512913646.0034.0018.0021.0017.0015.0015.00
    Cash Equivalents4.6%35.0033.0043.0048.0046.0051.0091.0012314416716515712713344.0030.0014.0020.0016.008.0012.00
  Net PPE-9.2%12.0013.0014.0014.0016.0012.009.008.007.005.004.002.001.001.000.000.000.001.002.002.001.00
  Goodwill0.2%5.005.005.005.005.005.005.005.005.00------------
Liabilities-0.3%34.0034.0038.0040.0043.0053.0038.0034.0034.0036.0029.0030.0029.0023.0024.0021.0024.0024.0021.0024.0024.00
  Current Liabilities21.8%14.0011.0014.0016.0018.0022.0016.0011.0011.0013.0013.0012.0012.0010.0011.007.009.009.007.009.007.00
Shareholder's Equity-19.2%58.0072.0085.0090.0011112214316618820520017612313240.0031.0013.0019.0016.0013.0011.00
  Retained Earnings-4.4%-409-392-374-352-327-303-273-244-219-198-181-164-148-135-126-117-116-110-104-99.35-97.99
  Additional Paid-In Capital0.9%468464460442438426417411407404381341272267167142130125119111109
Shares Outstanding0.9%153152152136134126126126126120121115---------
Float-------394---913---842---8.00--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations9.9%-13,521-15,001-17,471-24,460-29,152-14,615-25,899-25,113-15,814-14,267-13,159-16,592-10,766-9,255-521-3,208-3,792-4,328-317-4,653-5,702
  Share Based Compensation-3.3%3,7153,8433,9272,6473,3933,6433,4213,1302,9132,0992,6041,2514879152,86096.00137146180164152
Cashflow From Investing203.9%15,1044,970-1,58325,46115,801-31,073-8,8753,732-8,177-4,412-15,949-20,559-902-308-9.00-1.00-12.00-127-159-552-195
Cashflow From Financing-725.0%-66.00-8.0013,8971,4208,5964,9882,8381,04050520,64437,06367,5925,10098,61315,05919,542-2,2287,7558,3102,123-519

VXRT Income Statement

2023-12-31
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenue from Contract with Customer, Including Assessed Tax$ 7,379$ 107
Operating expenses:  
Research and development68,14281,054
General and administrative22,58429,386
Impairment of intangible assets04,254
Total operating expenses90,726114,694
Operating loss(83,347)(114,587)
Other income (expense):  
Interest income2,6521,247
Non-cash interest expense related to sale of future royalties(1,447)(1,305)
Gain on remeasurement of future royalty liability06,960
Other expense, net(62)(6)
Loss before income taxes(82,204)(107,691)
Provision for income taxes26167
Net loss$ (82,465)$ (107,758)
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)$ (0.57)$ (0.84)
Shares used to compute net loss per share, basic and diluted (in shares)144,819,781127,683,813
Comprehensive loss:  
Net loss$ (82,465)$ (107,758)
Unrealized gain (loss) on available-for-sale investments, net of tax298(225)
Comprehensive loss(82,167)(107,983)
Non Cash Royalty Revenue [Member]  
Revenue from Contract with Customer, Including Assessed Tax3,920107
Grant [Member]  
Revenue from Contract with Customer, Including Assessed Tax$ 3,459$ 0

VXRT Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash, cash equivalents and restricted cash$ 34,755$ 46,013
Short-term investments4,95849,704
Accounts receivable3,00820
Prepaid expenses and other current assets2,8153,714
Total current assets45,53699,451
Property and equipment, net11,73115,585
Right-of-use assets, net24,84025,715
Intangible assets, net4,2895,020
Goodwill4,5084,508
Other long-term assets9263,568
Total assets91,830153,847
Current liabilities:  
Accounts payable1,5845,514
Deferred grant revenue02,000
Other accrued current liabilities5,6348,084
Current portion of operating lease liability2,7032,228
Current portion of liability related to sale of future royalties3,80395
Total current liabilities13,72417,921
Operating lease liability, net of current portion17,38519,477
Liability related to sale of future royalties, net of current portion2,6235,621
Other long-term liabilities293231
Total liabilities34,02543,250
Commitments and contingencies (Note 9)
Stockholders’ equity:  
Preferred Stock: $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding as of December 31, 2023 or 202200
Common Stock: $0.0001 par value; 250,000,000 shares authorized as of December 31, 2023 and 2022; 153,959,853 shares issued and 153,452,833 shares outstanding as of December 31, 2023 and 134,199,429 shares issued and outstanding as of December 31, 20221513
Additional paid-in capital467,731437,992
Treasury Stock at cost, 507,020 shares and none as of December 31, 2023 and 2022, respectively(366)0
Accumulated deficit(409,574)(327,109)
Accumulated other comprehensive loss(1)(299)
Total stockholders’ equity57,805110,597
Total liabilities and stockholders’ equity$ 91,830$ 153,847
VXRT
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase II clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine, an oral vaccine platform, which is in preclinical stage; coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection; human papillomavirus therapeutic vaccine that targets HPV 16 and HPV 18 for cervical cancers and precancerous cervical dysplasia. The company has license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
 CEO
 WEBSITEhttps://vaxart.com
 INDUSTRYBiotechnology
 EMPLOYEES164

Vaxart Inc Frequently Asked Questions


What is the ticker symbol for Vaxart Inc? What does VXRT stand for in stocks?

VXRT is the stock ticker symbol of Vaxart Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vaxart Inc (VXRT)?

As of Fri Apr 12 2024, market cap of Vaxart Inc is 158.21 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VXRT stock?

You can check VXRT's fair value in chart for subscribers.

What is the fair value of VXRT stock?

You can check VXRT's fair value in chart for subscribers. The fair value of Vaxart Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Vaxart Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VXRT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Vaxart Inc a good stock to buy?

The fair value guage provides a quick view whether VXRT is over valued or under valued. Whether Vaxart Inc is cheap or expensive depends on the assumptions which impact Vaxart Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VXRT.

What is Vaxart Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 12 2024, VXRT's PE ratio (Price to Earnings) is -1.92 and Price to Sales (PS) ratio is 21.44. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VXRT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Vaxart Inc's stock?

In the past 10 years, Vaxart Inc has provided -0.341 (multiply by 100 for percentage) rate of return.